Bioventus expands hyaluronic acid product for osteoarthritis into Australia, New Zealand

Written by Alan Condon | August 13, 2019 | Print  |

Bioventus plans to expand Durolane, its hyaluronic acid joint-fluid osteoarthritis injection, into Australia and New Zealand.

Four things to know:

1. Durolane is used in the symptomatic treatment of mild to moderate hip osteoarthritis and mild to moderate osteoarthritis pain in the ankle, shoulder, elbow, wrist, fingers and toes.

2. The orthobiologic company is also launching another HA-based product, Durolane SJ, in both countries later this year.

3. Durolane SJ is used in the symptomatic treatment of mild to moderate osteoarthritis pain in the ankle, elbow, wrist, fingers and toes.

4. Both products are also indicated for pain following joint arthroscopy in the presence of osteoarthritis within three months of the operation.

More articles on biologics:
Laser Spine Institute co-founders now owe ex-business partner $300M+, judge rules
Academic panel to define best practices for outpatient stem cell procedure
The big trends, issues in spine shaping practices today


© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months